Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc
Bullboard Posts
User Avatar Image
(17)
•••
Comment by alphaseeking001on Dec 14, 2018 1:46pm
119 Views
Post# 29117035

RE:RE:I thought I was being patient (sort of) but jeez...

RE:RE:I thought I was being patient (sort of) but jeez...I sincerely hope the positive results will continue with the Merck trials.  While I suppose anything can happen, we seem to have enough confirmation now as to the mechanism of DPX that I would be surprised if in the same disease (OC) and with an even better drug (Keytruda) we don't get results that are at least as god as those with Incyte's drug?  If DPX's effects seen so far are largely due to a monotherapy effect... would we not expect further results to be similar?
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities